ZNRF4 Inhibitors
Chemical inhibitors of ZNRF4 can impact its function by targeting various signaling pathways and molecular processes that are crucial for its activity. PD 98059 and U0126 are selective inhibitors of MEK1/2, which are upstream of ERK1/2 in the MAPK signaling pathway. Inhibition of MEK1/2 by these chemicals results in decreased ERK1/2 phosphorylation, leading to reduced signaling through pathways that are essential for ZNRF4 activity. Similarly, LY294002 and Wortmannin are inhibitors of PI3K, a kinase upstream of Akt signaling. By blocking PI3K activity, these inhibitors can reduce the activation of Akt, which in turn may lead to diminished ZNRF4 function if it is regulated by the Akt pathway. SB203580 targets the p38 MAPK, another signaling molecule that can influence the activity of ZNRF4 by modulating the phosphorylation state of downstream targets that ZNRF4 may interact with.
Alternatively, SP600125 acts as an inhibitor of JNK, which is involved in controlling inflammatory responses and apoptosis, pathways that could also intersect with ZNRF4 signaling. By inhibiting JNK, SP600125 can disrupt downstream signaling events, potentially leading to a decrease in ZNRF4 activity. Rapamycin, by inhibiting mTOR, can affect central processes such as cell growth and proliferation, which ZNRF4 may regulate. This inhibition can result in the downregulation of cellular processes associated with ZNRF4 function. Furthermore, the proteasome inhibitors MG-132 and Bortezomib can lead to the accumulation of ubiquitinated proteins. Since ZNRF4 might be involved in the ubiquitin-proteasome pathway, these inhibitors can lead to functional inhibition of ZNRF4 by preventing proteasome-mediated protein degradation that ZNRF4 is possibly a part of. Additionally, Dasatinib and PP2, both Src family kinase inhibitors, can decrease ZNRF4 activity by inhibiting the Src kinases, which could be upstream of ZNRF4 signaling pathways. Lastly, Roscovitine, a CDK inhibitor, can prevent phosphorylation events necessary for ZNRF4 activity, thus potentially inhibiting its function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which in turn inhibits ERK1/2 phosphorylation. ZNRF4 is involved in pathways regulated by the ERK1/2 signaling. Inhibition of ERK1/2 by PD 98059 can lead to decreased activity of ZNRF4 due to reduced signaling through this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. PI3K is upstream of Akt signaling, which could intersect with ZNRF4-associated pathways. By blocking PI3K, LY294002 can inhibit Akt activation, thereby inhibiting ZNRF4 function if ZNRF4 is downstream of Akt. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. p38 MAPK is involved in stress responses and may intersect with ZNRF4's signaling pathways. By inhibiting p38 MAPK, SB203580 can lead to reduced phosphorylation of downstream targets that could be necessary for ZNRF4's functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in inflammatory responses and apoptosis. JNK signaling can influence ZNRF4 function, and inhibition by SP600125 could reduce ZNRF4's activity by limiting downstream signaling events. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor like LY294002, but it is irreversible. It can inhibit the PI3K/Akt pathway, leading to decreased activity of ZNRF4 if ZNRF4's function is regulated by this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor, and mTOR is a central regulator of cell growth and proliferation. Since ZNRF4 may be involved in these processes, inhibition of mTOR by Rapamycin can lead to downregulation of the cellular processes that ZNRF4 regulates. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that can lead to the accumulation of ubiquitinated proteins. If ZNRF4 is involved in the ubiquitin-proteasome pathway, inhibition of this pathway by MG-132 can lead to functional inhibition of ZNRF4 by preventing its mediated protein degradation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is another proteasome inhibitor that can affect the degradation of proteins involved in cell cycle regulation and apoptosis. By inhibiting the proteasome, Bortezomib can indirectly inhibit ZNRF4 function if it is reliant on proteasome-mediated processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, similar to PD 98059. By inhibiting MEK1/2, U0126 can block the downstream ERK1/2 signaling which may be essential for ZNRF4 activity, thereby inhibiting its function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Src kinases are involved in multiple signaling pathways that could intersect with ZNRF4 function. Inhibition of Src kinases by Dasatinib could lead to reduced ZNRF4 activity due to lowered signaling through related pathways. | ||||||